Shanghai Bio-Heart Biological Technology Hires Contract Research Organization for European Clinical Trial

MT NewswiresDec 30, 2021 12:16

Weekly IPO | A number of star companies sprinted to the Hong Kong Stock Exchange, and Weibo successfully returned to Hong Kong for a second listing

Popular IPOs such as Yonghe Medical and SF Express Tongcheng will make a group appearance next week; Baixinan, Jinli Permanent Magnet, and Shengnuo Pharmaceutical, the “first small nucleic acid drug” in China, passed the hearing.

富途資訊Dec 11, 2021 22:02 · IPO

IPO | Baixinan Biotech passed the Hong Kong Stock Exchange hearing and has not generated any product revenue since its establishment

On November 11, Capital Bank learned that Shanghai Baixinan Biotechnology Co., Ltd. passed the Hong Kong Stock Exchange hearing. According to the hearing, Baixinan Biotech is a leading innovative interventional cardiovascular device company in China. It currently focuses on the following two treatments: (i) fully degradable stent (BRS) therapy to address the unmet medical needs of Chinese patients in treating coronary or peripheral artery disease; and (ii) renal nerve block (RDN) therapy to address patients' unmet medical needs in treating uncontrolled hypertension and refractory hypertension. As of the last practical date, the company had one item in various stages of development

資本邦Nov 15, 2021 10:37

IPO News | Baixinan Biotech passed the Hong Kong Stock Exchange hearing. The company has a core product and eight other pipeline products under development

On November 10, Baixinan Biotech passed the Hong Kong Stock Exchange listing hearing.

智通財經Nov 11, 2021 09:01 · IPO

IPO Preview|Well-known institutions are sitting in Baixinan Biotech and are on the cusp of fully degradable stents that can be expected in the future

Mining has not dampened the enthusiasm for device IPOs in any way. Recently, a number of interventional medical device companies have poured into the Hong Kong stock market, making the market feel a small wave brought about by this racetrack, and this also brought an important opportunity for Baixinan Biotech to go public. The Zhitong Finance App observed that on September 13, Baixinan Biotech submitted a listing application to the main board of the Hong Kong Stock Exchange. Driven by factors such as an aging population, unhealthy diets and lifestyles, and environmental pollution, chronic diseases have become more and more common in the country in recent years. Heart disease and high blood pressure are among the most common fatal chronic diseases in patients in China. In this context, as a family, we are committed to a new one

智通財經Sep 15, 2021 19:23

IPO News | Baixinan Biotech once again submitted a listing to the Hong Kong Stock Exchange. Currently, there are no approved products for commercial sale

According to the Hong Kong Stock Exchange's disclosure on September 13, Baixinan Biotech submitted a listing application to the main board of the Hong Kong Stock Exchange. The company submitted forms to the Hong Kong Stock Exchange on February 26 and submitted hearing materials on June 16, which are now invalid.

智通財經Sep 14, 2021 09:35